Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep862 | Thyroid | ECE2020

Influence of care pathway on thyroid nodule surgery relevance

Castellnou Solene , Jean-Christophe Lifante , Polazzi Stephanie , Pascal Lea , Borson-Chazot Francoise , Duclos Antoine

Objective: Guidelines recommend using fine needle aspiration cytology (FNAC) to guide thyroid nodule surgical indication, however to what extent these guidelines are followed remains unclear. This study aimed to analyze the quality of the preoperative care pathway and the influence of the care pathway on surgical indications relevance.Design: Nationwide historical cohort study based on data from a sample (1/97th) of French health insurance beneficiaries....

ea0070aep617 | Pituitary and Neuroendocrinology | ECE2020

SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors

Castellnou Solene , Vasiljevic Alexandre , Lapras Veronique , Raverot Véronique , Alix Eudeline , Borson-Chazot Francoise , Jouanneau Emmanuel , Raverot Gerald , Hélène Lasolle

Context: Somatostatin receptor type 5 (SST5) is inconsistently expressed by corticotroph tumors, with higher expression found in corticotropinomas having ubiquitin-specific protease 8 (USP8) mutations.Aims: To study the correlation between characteristics of corticotropinomasand SST5 expression/USP8 mutation status; to describe the response to pasireotide in 5 patients.Design: Retrospective cohort study.Metho...

ea0101op-13-05 | Oral Session 13: TED | ETA2024

Efficacy of teprotumumab on medical and surgical resistant don

Lucia Carretti Anna , Kielwasser Gauthier , Peiffert Mathilde , Bogaciu Teodora , Thia-Soui-Tchonga Kim , Jouanneau Emmanuel , Lasolle Helene , Castellnou Solene , Manet Romain , Abeillon-du Payrat Juliette

Dysthyroid Optic Neuropathy (DON) is a rare but sight threatening complication of Graves orbitopathy (GO), secondary to optic nerve compression or optic nerve stretching. A previous study from our group showed that medical and surgical treatment of DON according to EUGOGO guidelines resulted in a significant recovery in 70% of DON. However 30% had only partial or no recovery. Teprotumumab is an Insulin Growth Factor -1Receptor inhibitor (IGF-1R) showing impressive results in t...